Recently, PAK4 was shown to suppress T cell response in melanoma, prostate cancer, and glioblastoma, which is consistent with an observed upregulation of intra-tumoral CD8 + T cells in PDA mouse model by PAK4 inhibitor PF-3758309 [10, 15–18]. This evidence concerns the gene CD8A and prostate carcinoma.